Related Experiment Video
Updated: Jun 28, 2026
Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment
Wenzhong William Min1, Christopher J Yuskaitis, Qijiang Yan
1St. Luke's-Roosevelt Institute for Health Sciences, Columbia University, 432 W. 58th St., Rm. 411, New York, NY 10019, USA.
Abstract:
Significant advances have been made in understanding the underlying defects of and developing potential treatments for Fragile X syndrome (FXS), the most common heritable mental retardation. It has been shown that neuronal metabotropic glutamate receptor 5 (mGluR5)-mediated signaling is affected in FX animal models, with consequent alterations in activity-dependent protein translation and synaptic spine functionality. We demonstrate here that a central metabolic regulatory enzyme, glycogen synthase kinase-3 (GSK3) is present in a form indicating elevated activity in several regions of the FX mouse brain. Furthermore, we show that selective GSK3 inhibitors, as well as lithium, are able to revert mutant phenotypes of the FX mouse. Lithium, in particular, remained effective with chronic administration, although its effects were reversible even when given from birth. The combination of an mGluR5 antagonist and GSK3 inhibitors was not additive. Instead, it was discovered that mGluR5 signaling and GSK3 activation in the FX mouse are coordinately elevated, with inhibition of mGluR5 leading to inhibition of GSK3. These findings raise the possibility that GSK3 is a fundamental and central component of FXS pathology, with a substantial treatment potential.
Insights
Glycogen synthase kinase-3 (GSK3) is highly active in Fragile X syndrome (FXS) mouse models. Inhibiting GSK3 or using lithium can reverse FXS phenotypes, suggesting GSK3 is a key target for FXS treatment.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Fragile X syndrome (FXS) is the most common heritable intellectual disability.
- FXS involves altered neuronal metabotropic glutamate receptor 5 (mGluR5) signaling and synaptic dysfunction.
- Understanding FXS pathology is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the role of glycogen synthase kinase-3 (GSK3) in FXS.
- To evaluate the therapeutic potential of GSK3 inhibitors and lithium in FXS mouse models.
- To explore the relationship between mGluR5 signaling and GSK3 activation in FXS.
Main Methods:
- Assessed GSK3 activity in FX mouse brains.
- Administered selective GSK3 inhibitors and lithium to FX mice.
- Investigated the combined effects of mGluR5 antagonists and GSK3 inhibitors.
- Analyzed mGluR5 signaling and GSK3 activation pathways.
Main Results:
- Elevated GSK3 activity was observed in multiple brain regions of FX mice.
- GSK3 inhibitors and lithium treatment reversed FXS-related phenotypes in mice.
- Lithium showed sustained efficacy with chronic administration, though effects were reversible.
- mGluR5 signaling and GSK3 activation are coordinately elevated in FXS mice, with mGluR5 inhibition reducing GSK3 activity.
Conclusions:
- GSK3 is a central component of FXS pathology.
- Targeting GSK3 presents significant therapeutic potential for Fragile X syndrome.
- The interplay between mGluR5 and GSK3 offers novel avenues for FXS treatment strategies.
More Related Videos
10:59Generation and Characterization of Human Induced Pluripotent Stem Cell-derived Astrocytes Lacking Fragile X Messenger Ribonucleoprotein
Published on: June 6, 2025
08:22A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene
Published on: September 16, 2019